Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.
$KALV
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2025 | $19.00 | Mkt Outperform | JMP Securities |
| 1/7/2025 | $30.00 | Buy | TD Cowen |
| 12/18/2024 | $22.00 | Buy | BofA Securities |
| 3/11/2022 | $48.00 → $42.00 | Buy | Needham |
| 12/10/2021 | $50.00 → $48.00 | Buy | Needham |
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
3 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00
TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00
BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00
10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)
SCHEDULE 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig's appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but remains a member of the Board and continues to serve on the Nominating and Corporate Governance Committee of the Board. The Board also approved Ms. Stuart's appointment to the Compensation Committee of the Board. "I am pleased to welcome Bethany to the Board of Directors of KalVista. Her extensive financial and operational experti
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX) (the "Company"), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. "We are delighted to welcome Dr. Reid to our Board of Directors. Laurence brings a remarkable track record as a company builder and biotech executive, with deep experience across business development, research and development strategy, and organizational growth," said Brian C. Thomas, PhD, CEO and founder of Metagenomi. "Laurence's insight and counsel will be invaluable
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)
US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si
KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric population and reveal higher attack frequency than previously believed KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet need for safe, effective and easy-to-use on-demand treatments, present
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:30 p.m. GMT The live audio webcast of each presentation will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of the events. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedi
US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host conference call Tuesday, November 11th at 8:30 a.m. ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. "The US launch of EKTERLY is progressing with si
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available on the site approximately two hours after completion of the event. About KalVista Pharmaceuticals, Inc. KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered
-EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema- -Initiated US EKTERLY launch in July; received 460 patient start forms through August- -European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October- -$191M in cash, providing runway into 2027- -Management to host conference call today at 8:30 a.m. ET- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. "This quarter marked a defining mome
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)
SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)